Natural history of transthyretin Val30Met familial amyloid polyneuropathy: Analysis of late-onset cases from non-endemic areas

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 2, 2012, Pages 152-158

  Koike, Haruki ^a   Tanaka, Fumiaki ^a   Hashimoto, Rina ^a   Tomita, Minoru ^a   Kawagashira, Yuichi ^a   Iijima, Masahiro ^a   Fujitake, Junko ^b   Kawanami, Toru ^c   Kato, Takeo ^c   Yamamoto, Masahiko ^d   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN; METHIONINE; PREALBUMIN; VALINE;

ADULT; AGE; AGE AT DEATH; AGED; AMYLOIDOSIS; ANEMIA; ARM; ARTICLE; ARTIFICIAL HEART PACEMAKER; CACHEXIA; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR PARAMETERS; CAUSE OF DEATH; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; COMPLETE HEART BLOCK; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; ELECTROPHYSIOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART AMYLOIDOSIS; HEART FAILURE; HEART THORAX INDEX; HEART VENTRICLE SEPTUM; HEMOGLOBIN BLOOD LEVEL; HOARSENESS; HUMAN; IMPLANTATION; INTERVENTRICULAR SEPTUM THICKNESS; KIDNEY FAILURE; LATE ONSET FAMILIAL AMYLOID POLYNEUROPATHY; LEG; LIMB PAIN; MALE; MOTOR NERVE CONDUCTION; MOTOR NEUROPATHY; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION DISORDER; NERVE POTENTIAL; OCULAR AMYLOIDOSIS; ONSET AGE; ORTHOSTATIC SYMPTOM; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SECONDARY INFECTION; SENSORY NERVE ACTION POTENTIAL; SENSORY NERVE CONDUCTION; SENSORY NEUROPATHY; SEX DIFFERENCE; SUDDEN DEATH; SURAL NERVE; SYMPTOM; SYNCOPE; TIBIAL NERVE; ULNAR NERVE; URINARY SYMPTOM; WHEELCHAIR;

ACTION POTENTIALS; AGE OF ONSET; AGED; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMEGALY; CAUSE OF DEATH; DISEASE PROGRESSION; ENDEMIC DISEASES; FEMALE; FOLLOW-UP STUDIES; HEART; HEART DISEASES; HUMANS; JAPAN; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; PACEMAKER, ARTIFICIAL; PAIN; PREALBUMIN; RETROSPECTIVE STUDIES; SENSATION DISORDERS;

EID: 84855598855     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-301299     Document Type: Article

References (50)

1. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 1976;590:1-64.
2. Ikeda S, Hanyu N, Hongo M, et al. Hereditary generalized amyloidosis with polyneuropathy: clinicopathological study of 65 Japanese patients. Brain 1987;110:315-37. (Pubitemid 17055815)
3. Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-4.
4. Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:515-21.
5. Reilly MM, Adams D, Booth DR, et al. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain 1995;118:849-56.
6. Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-7. (Pubitemid 34298536)
7. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62. (Pubitemid 41043725)
8. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23. (Pubitemid 47512065)
9. Plante-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-8. (Pubitemid 47256013)
10. Said G, Planté-Bordeneuve V. Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci 2009;284:149-54.
11. Koike H, Sobue G. Diagnosis of familial amyloid polyneuropathy: wide-ranged clinicopathological features. Expert Opin Med Diagn 2010;4:323-31.
12. Koike H, Misu K, Ikeda S, et al. Type I (Transthyretin Met30) familial amyloid polyneuropathy in Japan: early- versus late-onset form. Arch Neurol 2002;59:1771-6. (Pubitemid 35340488)
13. Sobue G, Koike H, Misu K, et al. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid 2003;10 Suppl 1:32-8. (Pubitemid 37372565)
14. Dardiotis E, Koutsou P, Papanicolaou EZ, et al. Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 2009;16:32-7.
15. Saporta MA, Zaros C, Cruz MW, et al. Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families. Eur J Neurol 2009;16:337-41.
16. Kato-Motozaki Y, Ono K, Shima K, et al. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci 2008;270:133-40.
17. Koike H, Kawagashira Y, Iijima M, et al. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol 2008;255:1526-33.
18. Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011;18:53-62.
19. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-16. (Pubitemid 23125854)
20. Sato T, Ando Y, Susuki S, et al. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 2006;580:491-6. (Pubitemid 43089677)
21. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30.
22. Terazaki H, Ando Y, Fernandes R, et al. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006;86:23-31. (Pubitemid 43250965)
23. Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010;8:74.
24. Macedo B, Magalhães J, Batista AR, et al. Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res 2010;62:514-22.
25. Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004;63:129-38. (Pubitemid 38943790)
26. Benson MD, Teague SD, Kovacs R, et al. Rate of Progression of Transthyretin Amyloidosis. Am J Cardiol 2011;108:285-9.
27. Misu K, Hattori N, Nagamatsu M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met 30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan; clinicopathological and genetic features. Brain 1999;122:1951-62. (Pubitemid 29473866)
28. Koike H, Morozumi S, Kawagashira Y, et al. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid 2009;15:1-7.
29. Nakazato M, Ikeda S, Shiomi K, et al. Identification of a novel transthyretin variant (Val30-Leu) associated with familial amyloidotic polyneuropathy. FEBS Lett 1992;306:206-8.
30. Saraiva MJ, Costa PP, Goodman DS. Genetic expression of a tansthyretin mutation in typical and late-onset Portuguese families with familial amyloidotic polyneuropathy. Neurology 1986;36:1413-17. (Pubitemid 17175761)
31. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123:1495-504. (Pubitemid 30420948)
32. Denier C, Ducot B, Husson H, et al. A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol 2007;254:1684-8.
33. Koike H, Hirayama M, Yamamoto M, et al. Age associated axonal features in HNPP with 17p11.2 deletion in Japan. J Neurol Neurosurg Psychiatry 2005;76:1109-14. (Pubitemid 41081286)
34. Ikeda S. Cardiac amyloidosis: heterogenous pathogenic backgrounds. Intern Med 2004;43:1107-14. (Pubitemid 40074144)
35. Hörnsten R, Pennlert J, Wiklund U, et al. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010;17:63-8.
36. Ando Y, Araki S, Ando M. Transthyretin and familial amyloidotic polyneuropathy. Intern Med 1993;32:920-2.
37. Ikegawa S, Araki S, Nagata J, et al. Review of clinical records and therapeutic trials to familial amyloidotic polyneuropathyestudy of 50 cases in Kumamoto (1967-1984) (In Japanese). Rinsho Shinkeigaku 1986;26:175-9. (Pubitemid 16147139)
38. Andrade C. A peculiar form of peripheral neuropathy: familial generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-27.
39. Coutinho P, Martins da Silva A, Lopes Lima J, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica, 1980:88-98.
40. Kodaira M, Morita H, Shimojima Y, et al. Electrophysiological features of familial amyloid polyneuropathy in endemic area. Amyloid 2011;18:10-18.
41. Nakazato M, Tanaka M, Yamamura Y, et al. Abnormal transthyretin in asymptomatic relatives in familial amyloidotic polyneuropathy. Arch Neurol 1987;44:1275-8. (Pubitemid 18004938)
42. Ikeda S, Nakano T, Yanagisawa N, et al. Asymptomatic homozygous gene carrier in a family with type I familial amyloid polyneuropathy. Eur Neurol 1992;32:308-13.
43. Yoshinaga T, Nakazato M, Ikeda S, et al. Homozygosity for the transthyretin-Met30 gene in three Japanese siblings with type I familial amyloidotic polyneuropathy. Neurology 1992;42:2045-7.
44. Tojo K, Tsuchiya-Suzuki A, Sekijima Y, et al. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy. Amyloid 2010;17:32-5.
45. Araki S, Kurihara T, Tawara S, et al. Familial amyloidotic polyneuropathy in Japanese. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica, 1980:67-77.
46. Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994;235:479-85. (Pubitemid 24212814)
47. Koike H, Ando Y, Ueda M, et al. Distinct characteristics of amyloid deposits in earlyand late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 2009;287:178-84.
48. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.
49. Miyazaki Y, Koike H, Akane A, et al. Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid 2011;18:87-90.
50. Tashima K, Ando Y, Terazaki H, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 1999;171:19-23. (Pubitemid 29525573)